Health
Healthcare
Medical

BioScrip

$2.39
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (2.14%) Today
+$0.05 (2.14%) Today

Why Robinhood?

You can buy or sell BioScrip and other stocks, options, ETFs, and crypto commission-free!

About

BioScrip, Inc. engages in the provision of home infusion and home care management solutions. It partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. Read More The company was founded in 1996 and is headquartered in Denver, CO.

Employees
2,043
Headquarters
Denver, Colorado
Founded
1996
Market Cap
299.70M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
740.63K
High Today
$2.43
Low Today
$2.34
Open Price
$2.39
Volume
187.56K
52 Week High
$4.14
52 Week Low
$2.29

Collections

Health
Healthcare
Medical
Pharmaceutical
Medical Devices

News

Markets Insider21h

HC Group Holdings III, Inc. -- Moody's places HC Group Holding's ratings under review for upgrade following the announced merger with BioScrip

HC Group Holdings III, Inc. -- Moody's places HC Group Holding's ratings under review for upgrade following the announced merger with BioScrip...

1,793
MarketWatch21h

BioScrip's stock extends plunge after merger terms disappoint, but analyst recommends remaining bullish

Shares of BioScrip Inc. BIOS, -15.83% tumbled 9.0% toward a 9-month low in midday trade Monday, extending the sharp reversal suffered early in the previous session as investors digested the terms of the company's merger deal with Option Care Enterprises Inc. On Friday, the stock soared as much as 71% in premarket trade, and as much as 8.0% during the regular session, before pulling a sharp U-turn to close down 20.3%. Canaccord Genuity analyst Richard Close said that investors may have to suffer some short-t...

491
Yahoo FinanceMar 18

BioScrip (BIOS) Reports Loss in Q4, Both Margins Contract

BioScrip Inc. BIOS reported a loss from continuing operations of 14 cents per share for fourth-quarter 2018, wider than the Zacks Consensus Estimate. The figure deteriorated from the year-ago loss of 3 cents. At the end of 2018, loss from continuing operations was 49 cents a share, narrower than the year-ago loss of 59 cents. Revenues Net revenues of $183.6 million in the fourth quarter rose 0.5% year over year. This figure however missed the Zacks Consensus Estimate of $188 million. For the ful...

1,087

Earnings

-$0.15
-$0.11
-$0.06
-$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.03 per share
Actual
-$0.14 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.